FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease - CNBC

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the dis… [+1350 chars]